Stock 002252 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Shanghai RAAS Blood Products Co., Ltd. Stock

Equities

002252

CNE100000C31

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
7.1 CNY -0.84% Intraday chart for Shanghai RAAS Blood Products Co., Ltd. +1.00% -11.25%
May. 29 Shanghai RAAS Blood Products Co., Ltd. Implements 2023 Final Profit Distribution Plan of A Shares, Payable on 05 June 2024 CI
May. 22 Shanghai Raas Blood Products Co., Ltd. Approves 2023 Profit Distribution Plan CI

Financials

Sales 2024 * 8.73B 1.21B Sales 2025 * 9.67B 1.34B Capitalization 46.89B 6.48B
Net income 2024 * 2.25B 310M Net income 2025 * 2.52B 348M EV / Sales 2024 * 4.73 x
Net cash position 2024 * 5.6B 773M Net cash position 2025 * 8.58B 1.18B EV / Sales 2025 * 3.96 x
P/E ratio 2024 *
20.9 x
P/E ratio 2025 *
18.7 x
Employees 3,254
Yield 2024 *
0.21%
Yield 2025 *
0.21%
Free-Float 69.53%
More Fundamentals * Assessed data

Chart Shanghai RAAS Blood Products Co., Ltd.

Dynamic Chart

Latest news about Shanghai RAAS Blood Products Co., Ltd.

Shanghai RAAS Blood Products Co., Ltd. Implements 2023 Final Profit Distribution Plan of A Shares, Payable on 05 June 2024 CI
Shanghai Raas Blood Products Co., Ltd. Approves 2023 Profit Distribution Plan CI
GRIFOLS CEO SAYS CAN CONFIRM SHANGHAI RAAS TRANSACTION WILL CLO… RE
Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
RAAS Blood Products' 2023 Profit Falls 5% Despite 21% Revenue Growth MT
Shanghai RAAS Blood Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake RE
RAAS Blood Products Gets Regulatory Nod to Trial Drug for Bleeding Disorders MT
Grifols says due diligence was carried out on Shanghai RAAS stake sale RE
Grifols' shares tumble as restructuring costs hit annual profit RE
S&P Maintains Grifols' Rating, Stable Outlook Amid Expected Deleveraging MT
S&P keeps Grifols at 'B+', sees leverage decreasing in 2024 RE
ECB probes banks over exposure to Spanish drugmaker Grifols: sources RE
ECB sounds out lenders on exposure to Spanish drugmaker Grifols - sources RE
The Ibex-35 rebounds without leaving the range of the last month and a half. RE
More news

Analyst Recommendations on Shanghai RAAS Blood Products Co., Ltd.

S&P Maintains Grifols' Rating, Stable Outlook Amid Expected Deleveraging MT
More recommendations

Press releases Shanghai RAAS Blood Products Co., Ltd.

Shanghai RAAS Blood Products : Grifols and Shanghai RAAS close their strategic alliance in China AQ
More press releases

News in other languages on Shanghai RAAS Blood Products Co., Ltd.

Point marchés-L'Europe clôture en hausse, l'économie de la zone euro montre des signes d'amélioration
Grifols dice se ha cumplido la debida diligencia en la venta de la participación en Shanghai RAAS 
Actualización de las fuertes variaciones del día: Drax y UMG seducen, mientras que Amadeus y Grifols decepcionan
Grifols dice que está en vías de reducir su ratio de deuda
Les actions en mouvement : Euroapi, Nexity, AMS-Osram ... des beaux cartons aujourd'hui
More news

Quotes and Performance

1 day-0.84%
1 week+1.00%
1 month-1.11%
3 months-1.39%
6 months-10.69%
Current year-11.25%
More quotes

Highs and lows

1 week
7.00
Extreme 7
7.30
1 month
7.00
Extreme 7
7.63
Current year
5.93
Extreme 5.93
8.60
1 year
5.93
Extreme 5.93
8.68
3 years
4.98
Extreme 4.98
8.68
5 years
4.98
Extreme 4.98
11.16
10 years
4.98
Extreme 4.98
26.67
More quotes

Managers and Directors - Shanghai RAAS Blood Products Co., Ltd.

Managers TitleAgeSince
Jun Xu CEO
 Chief Executive Officer 60 11-12-31
Le Qi Chen DFI
 Director of Finance/CFO 37 21-10-25
Wei Bing Hu CHM
 Chairman 60 03-03-02
Members of the board TitleAgeSince
Tomás Dagá Gelabert BRD
 Director/Board Member 68 20-05-19
Yue Wen Zheng BRD
 Director/Board Member 62 07-04-26
David Bell BRD
 Director/Board Member 70 20-05-19
More insiders

ETFs positioned on Shanghai RAAS Blood Products Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.71% 2 M€ -14.14%
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
0.69% 2 M€ -18.79% -
More ETFs positioned on Shanghai RAAS Blood Products Co., Ltd.

Quotes

Date Price Change Volume
24-05-31 7.1 -0.84% 29,419,770
24-05-30 7.16 -.--% 25,635,800
24-05-29 7.16 +1.13% 27,969,840
24-05-28 7.08 -0.42% 21,709,160
24-05-27 7.11 +1.14% 26,795,820

End-of-day quote Shenzhen S.E., May 30, 2024

More quotes

Company Profile

Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin). China accounts for 96.6% of net sales.
Sector
Pharmaceuticals
Calendar
2024-08-27 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai RAAS Blood Products Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
7.1 CNY
Average target price
6.55 CNY
Spread / Average Target
-7.75%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. Stock Shanghai RAAS Blood Products Co., Ltd.
-11.25% 6.48B
CSL LIMITED Stock CSL Limited
-2.29% 89.87B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-3.95% 37.57B
BIOGEN INC. Stock Biogen Inc.
-13.07% 32.75B
UCB Stock UCB
+63.05% 26.47B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-22.14% 14.25B
INCYTE CORPORATION Stock Incyte Corporation
-7.96% 12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.33% 11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-46.33% 10.84B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.77% 9.11B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 002252 Stock